SHAREHOLDER ALERT: Weiss Law Investigates Infinity Pharmaceuticals, Inc.

NEW YORK, Feb. 28, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI), in connection with its proposed merger with MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI Pharma").  Under the terms of the merger agreement, Infinity will become a wholly owned subsidiary of MEI Pharma.  Pursuant to an exchange ratio set forth in the merger agreement, MEI Pharma shareholders are expected to own approximately 58.0% and Infinity shareholders are expected to only own approximately 42.0% of the outstanding equity of the combined company immediately following the merger. 

If you own Infinity shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/infi 
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7^th Floor
New York, NY  10007
(212) 682-3025
(888) 593-4771
[email protected]

Weiss Law is investigating whether (i) Infinity's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration adequately compensates Infinity shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. 

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

SOURCE Weiss Law

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED